Cardiol Therapeutics Inc. Class A Common Shares (CRDL)
- Headquarters
- United States
- Employees
- 18
- Market Cap
- $139M
About Cardiol Therapeutics Inc. Class A Common Shares
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
SentiSense also tracks daily options readings for Cardiol Therapeutics Inc. Class A Common Shares: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Cardiol Therapeutics Inc. Class A Common Shares stock analysis, sentiment tracking, and market intelligence on SentiSense.